Results 171 to 180 of about 20,052 (248)

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. [PDF]

Nat Med
Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM, BELIEVE trial investigators.   +10 more
europepmc   +1 more source

Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) arises from dysregulated interactions between nutrient delivery, adipose tissue lipid handling and liver lipid metabolism, which collectively coalesce to drive inflammatory signalling leading to metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis. Recent clinical
Evangelia E. Tsakiridis, Gregory R. Steinberg   +1 more
wiley   +1 more source

Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm. [PDF]

Reports (MDPI)
Marzolla V, Gorini S, Caprio M, Infante M.   +3 more
europepmc   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition [PDF]

, 2015

core   +1 more source

Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Kidney and cardiovascular diseases are highly prevalent among patients with Type 1 diabetes. To date, no randomised clinical trial has reported on the impact of novel cardio‐kidney‐metabolic (CKM) therapies (GLP‐1RA and SGLT2i) on kidney function in this population.
M. Luiza Caramori, Enrico Repetto, Christopher Perkins, Ambarish Pandey, Peter Rossing   +4 more
wiley   +1 more source

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study). [PDF]

Cureus
Kapoor N, Kalra S, Naskar A, Shaikh S, Das S, Kota S, Bhattacharya S, Bhattacharya R, Giri R, Karnik N, Parise G, Mangipudi A, Ghosh A, Dange A, Khandelwal D, Chaudhari M, Deogaonkar N, Shamanna P, Sorate S, Saklecha S, Samadhan S, Varade D, Shembalkar J, Bangar K, Lomte N, Mayabhate M, Kapure N, Sharma A, Vaddem R, Jaiswal M.   +29 more
europepmc   +1 more source

Unimolecular GLP‐1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta‐Cell Survival and Glycaemic Regulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To characterise the metabolic benefits of a GLP‐1/apelin hybrid peptide, namely exendin‐4‐linker‐apelin (ELA), and associated acylated forms, including ELA‐Lys12(γGluPal), ELA‐Lys27(γGluPal) and ELA‐Lys38(γGluPal). Methods Concentration‐ and receptor‐dependent effects of the peptides on insulin secretion and beta‐cell turnover were ...
Ananyaa Sridhar, Ethan S. Palmer, Sarah L. Craig, Elzbieta Krason‐Kidzinska, Nigel Irwin, Finbarr P. M. O'Harte   +5 more
wiley   +1 more source

Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study. [PDF]

Diabetes Metab Syndr Obes
Bayram-Ozgur D, Demirtürk E, Sar Y.
europepmc   +1 more source

Obesity and Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Literature Review on Pathophysiology and Treatment

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) represents a key hepatic manifestation of obesity and systemic metabolic dysfunction and is a leading cause of chronic liver disease worldwide. Obesity‐driven mechanisms, including adipose tissue dysfunction, insulin resistance and increased free fatty acid flux to the liver ...
Michael Romanos, Juan M. Garcia Cordova, Jose Villamarin, Juan D. Pazmino Zurita, Andres Acosta   +4 more
wiley   +1 more source

Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To describe obesity treatments in real‐world settings after discontinuation of semaglutide or tirzepatide and variability in weight change post‐discontinuation. Materials and Methods This retrospective cohort study used electronic health records from 1 January 2021, to 30 June 2025, in a large health system in Ohio and Florida.
Hamlet Gasoyan, Rebecca Schulte, Christopher B. Boyer, Nicholas J. Casacchia, W. Scott Butsch, Phuc Le, Ali Aminian, Marcio L. Griebeler, Bartolome Burguera, Michael B. Rothberg   +9 more
wiley   +1 more source